CION Ameerpet
Hodgkin lymphoma is a cancer of the lymphatic system defined by a single distinctive cell. It is uncommon, highly treatable and — for many people — curable. This guide explains what it is, its subtypes, symptoms and how CION plans care.
Hodgkin lymphoma — long known as Hodgkin’s disease — is a cancer of the lymphatic system, the body’s network of lymph nodes and vessels that helps fight infection. It develops when a type of white blood cell (a B-lymphocyte) in the lymph nodes becomes abnormal and multiplies out of control. What makes it distinctive is a single, unmistakable cell: the Reed-Sternberg cell. Finding these large, abnormal cells in a lymph node biopsy is what separates Hodgkin lymphoma from every other lymphoma.
Hodgkin lymphoma usually starts in lymph nodes in the neck, chest or armpit, and tends to spread in an orderly, predictable way from one node group to the next — a pattern that helps make it so treatable. It is uncommon, but it has an unusual age distribution, most often affecting young adults aged roughly 15 to 35, and then people over 55. It is one of the most treatable cancers known, and for many people it is curable.
This guide explains what Hodgkin lymphoma is, the role of the Reed-Sternberg cell, its subtypes, the symptoms to know, and how it is diagnosed and treated. For the wider picture of lymphoma care, see our Lymphoma hub and the Lymphoma Treatment in Hyderabad page.
Hodgkin lymphoma is defined by the Reed-Sternberg cell — a large, abnormal B-cell first described by Dorothy Reed and Carl Sternberg over a century ago. Its presence in a lymph-node biopsy is the single feature that distinguishes Hodgkin lymphoma from all non-Hodgkin lymphomas, and these cells typically carry the marker CD30, which is checked by immunohistochemistry and can also be a therapy target. (Source: WHO Classification of Haematolymphoid Tumours, as referenced in NCCN and ESMO Hodgkin lymphoma guidelines.)
The most common first sign is a painless swollen lymph node. Many symptoms overlap with ordinary infections — but ones that are persistent or unexplained deserve a check. For the full detail, see Hodgkin lymphoma symptoms.
A firm, painless lump — most often in the neck, above the collarbone, in the armpit or the groin — that does not settle over a few weeks. This is the classic first sign.
Drenching night sweats, unexplained fever, and weight loss without trying. Doctors group these three together as B symptoms because they influence staging and treatment.
Persistent whole-body itching without a rash, and ongoing tiredness that rest does not fix, are recognised features of Hodgkin lymphoma.
Rarely, affected nodes ache soon after drinking alcohol — an unusual but well-described clue that can point towards Hodgkin lymphoma specifically.
Because Hodgkin lymphoma is so treatable, getting the diagnosis, subtype and staging exactly right — and using the least therapy needed — matters enormously. That is where a coordinated, guideline-led team makes the difference.
Expert haematopathology review confirms the Reed-Sternberg cells and subtype on biopsy, with CD30/CD15 immunohistochemistry — so treatment is built on a precise diagnosis, not a best guess.
CION delivers chemotherapy, antibody therapy, immunotherapy and precision radiation (IMRT) directly, and coordinates stem-cell transplant through accredited partner facilities when it is needed for relapsed disease.
Every case is discussed by a multidisciplinary tumour board following NCCN and ESMO guidance, balancing cure with protecting your long-term health. Meet our lymphoma specialists.
We're never more than 30 minutes away. Same panel of specialists at every centre. Same tumour board reviews. Same NCCN protocols. Pick the closest one and call directly — or let us pick for you.
CION Ameerpet
CION Kukatpally
CION L.B. Nagar
CION Tolichowki
CION Masab Tank
CION Banjara Hills
CION Kompally
CION Balanagar
CION Siddipet
CION Sangareddy
Not sure which centre fits best? Tell us where you are — we'll suggest the closest one with the right specialists.
Help me pick the right centreTravelling for treatment? We may have a centre right where you are.
Don't see your city? Call 18002028726 — we'll find your nearest CION partner centre.
Trained at AIIMS, Tata Memorial, and leading international centres. Combined 150+ years of experience. Every complex case is reviewed by 3+ of them — together.
MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)
MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)
MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)
MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)
MBBS, MS(General Surgery), M.Ch(Surgical Oncology), FMAS, FARIS(Ongoing)
MBBS, MS (General Surgery), DrNB (Surgical Oncology), FALS Oncology
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationShare your name and number — we'll call you back within 30 minutes to schedule your consultation.
Just received a Hodgkin lymphoma diagnosis, want to understand what your subtype and stage mean, or need a second opinion before treatment? CION’s lymphoma team is here.
Hodgkin lymphoma is not a single disease. It divides into two main groups, and knowing the exact subtype — confirmed on biopsy and immunohistochemistry — shapes the treatment plan and the outlook.
About 95% of cases are classical Hodgkin lymphoma, which contains the classic Reed-Sternberg cells carrying CD30 and usually CD15. It has four subtypes: nodular sclerosis (the most common, especially in young adults), mixed cellularity, lymphocyte-rich and lymphocyte-depleted. Read the full breakdown on our classical Hodgkin lymphoma & its subtypes page, and the common nodular sclerosis Hodgkin lymphoma subtype in detail.
The remaining ~5% is nodular lymphocyte-predominant Hodgkin lymphoma. Instead of classic Reed-Sternberg cells, it shows a different variant cell (a “popcorn” cell) and behaves more indolently, so it is often managed more conservatively. It carries CD20 rather than CD30 — a distinction that can guide antibody-based treatment.
Confirming Hodgkin lymphoma — and pinning down the subtype and stage — follows a clear, step-by-step pathway. CION delivers biopsy coordination, expert pathology review, staging imaging and blood work directly.
The diagnosis depends on removing a whole affected node (an excisional biopsy) so the pathologist can study its structure and find the Reed-Sternberg cells. A small needle sample alone is often not enough to confirm Hodgkin lymphoma. Immunohistochemistry then tests markers such as CD30 and CD15 to confirm classical Hodgkin lymphoma and rule out look-alikes.
Once confirmed, a PET-CT scan shows how far the disease has spread and forms the basis of staging (stages I to IV). Blood tests and, in some cases, a bone-marrow assessment complete the picture. Accurate staging is what lets the team choose the right amount of treatment — enough to cure, but no more than needed.
At CION, every Hodgkin lymphoma case is reviewed by a multidisciplinary tumour board before a plan is finalised, following NCCN and ESMO guidance. See what the full pathway looks like on our Lymphoma Treatment in Hyderabad page.
Because most Reed-Sternberg cells in classical Hodgkin lymphoma carry the marker CD30, that marker is not only used to confirm the diagnosis — it is also a treatment target. Anti-CD30 antibody-based therapy attaches to CD30 on the cancer cells, and immune-checkpoint approaches can re-activate the immune system in selected relapsed disease. (Source: NCCN and ESMO Hodgkin lymphoma guidelines.) Your team will explain the exact protocol — regimen names are covered on the Treatment page.
The plan depends on the subtype, stage, risk features and your overall health, and is set by the multidisciplinary tumour board. We describe treatments here by their type and mechanism; specific drug regimen names are covered on the Treatment page. The main building blocks are:
The backbone of Hodgkin lymphoma treatment is combination chemotherapy, which is highly effective, especially for early-stage disease. The number of cycles is tailored to the stage, and treatment response is often checked with an interim PET-CT to fine-tune the plan. CION’s medical oncology team delivers systemic therapy directly.
For some early-stage cases, a short course of precision radiation therapy (IMRT) to the involved node areas is added after chemotherapy. Modern techniques shape the beam tightly to reduce dose to healthy tissue — an important consideration given how many patients are young and cured. CION delivers IMRT directly.
Because classical Hodgkin cells usually carry CD30, anti-CD30 antibody-based therapy is an option in selected cases, and immune-checkpoint immunotherapy is used in some relapsed or refractory disease. CION delivers antibody therapy and immunotherapy in-house.
If Hodgkin lymphoma returns, further treatment — sometimes followed by a stem-cell transplant — can still be curative. CION coordinates transplant through accredited partner facilities while managing the surrounding care directly. Read more on options for relapsed Hodgkin lymphoma.
Hodgkin lymphoma has one of the best outlooks of any cancer. Across published international series, long-term survival is commonly reported at around 80–90%, and is higher still for early-stage disease found and treated promptly. For comparison, the common non-Hodgkin subtype diffuse large B-cell lymphoma is typically cited at around 60–70% (per published series and NCCN/ESMO-referenced data). These are population figures, not personal predictions — outcomes vary by individual, by stage, age and how the disease responds. For the detailed, attributed numbers, see our Hodgkin lymphoma survival & cure rates page.
Because so many people are cured — and many are young at diagnosis — modern Hodgkin lymphoma care focuses just as much on survivorship: using the least treatment needed, monitoring for late effects, and supporting long-term health. CION provides survivorship follow-up directly as part of every plan.
This page is the pillar for our Hodgkin lymphoma cluster. Explore the connected guides for the detail you need:
Best Lymphoma Hospital in Hyderabad · Lymphoma Treatment in Hyderabad · Best Lymphoma Doctors in Hyderabad
Because Hodgkin lymphoma is so treatable, getting the details right the first time is worth a second opinion — especially in these situations:
CION offers a dedicated, free written second-opinion service. You deserve a plan built around healing, not billing — with transparent costs explained up front. Request your free second opinion or call 18002028726.
Get a free written second opinion from CION’s lymphoma tumour board — especially valuable if the subtype or stage is uncertain, or if you want to confirm the plan before treatment begins.
These aren't paid endorsements or written reviews. These are video testimonials from real patients and families — recorded on their own phones, in their own words. Pick any one. Watch it. Then decide.
Read all 800+ reviews on Google
Start Your Story. Book Free Consultation.Hodgkin lymphoma — historically called Hodgkin’s disease — is a cancer of the lymphatic system, the network of nodes and vessels that helps the body fight infection. It is defined by a specific abnormal cell called the Reed-Sternberg cell, a large, distinctive cancer cell seen under the microscope. This single feature is what separates Hodgkin lymphoma from all the other lymphomas, which are grouped together as non-Hodgkin lymphoma. Hodgkin lymphoma usually begins in lymph nodes in the neck, chest or armpit and tends to spread in an orderly way from one node group to the next. It is uncommon but highly treatable, and for many people curable. Learn more about care pathways on our Lymphoma Treatment in Hyderabad page.
The Reed-Sternberg cell is a large, abnormal B-lymphocyte with two or more nuclei, often described as having an “owl-eye” appearance. Finding these cells in a lymph node biopsy is the defining hallmark of classical Hodgkin lymphoma. Their presence — and the surrounding mix of normal immune cells — is exactly what a pathologist looks for to confirm the diagnosis and separate Hodgkin from non-Hodgkin lymphoma. Reed-Sternberg cells typically carry the marker CD30, and often CD15, which are checked by immunohistochemistry on the biopsy tissue. In the nodular lymphocyte-predominant subtype, a different variant cell is seen instead. Because the whole diagnosis rests on correctly identifying these cells, expert haematopathology review of the biopsy is essential.
Hodgkin lymphoma is divided into two broad groups. Classical Hodgkin lymphoma accounts for roughly 95% of cases and contains classic Reed-Sternberg cells; it has four subtypes — nodular sclerosis, mixed cellularity, lymphocyte-rich and lymphocyte-depleted. Read more on our classical Hodgkin lymphoma & subtypes page and the common nodular sclerosis subtype. The second group, nodular lymphocyte-predominant Hodgkin lymphoma, is rarer, behaves differently and is often managed more conservatively. Knowing the exact subtype — confirmed on biopsy and immunohistochemistry — helps the team plan treatment precisely, which is why CION coordinates expert pathology review for every case.
The exact cause of Hodgkin lymphoma is not fully known, and in most people no clear cause is ever found. It is not something you catch or pass on. Several factors are linked to a modestly higher risk: a past infection with the Epstein-Barr virus (the glandular-fever virus), a weakened immune system (for example from HIV or long-term immune-suppressing medicines), and a family history of the disease. Hodgkin lymphoma has a distinctive age pattern — it peaks in young adults aged roughly 15 to 35 and again in people over 55. Importantly, having a risk factor does not mean you will develop the disease, and most people diagnosed have none of them. If you have a persistent, painless swollen node, it is worth having it checked — see Hodgkin lymphoma symptoms.
Diagnosis rests on a lymph node biopsy — ideally removing a whole node (excisional biopsy) so the pathologist can study its architecture and find Reed-Sternberg cells. A needle sample alone is often not enough. Immunohistochemistry then checks markers such as CD30 and CD15 to confirm classical Hodgkin lymphoma and rule out mimics. Once confirmed, staging shows how far the disease has spread, using a PET-CT scan and often a bone-marrow assessment, alongside blood tests. CION delivers biopsy coordination, expert haematopathology review, PET-CT staging and blood work directly, and every case is discussed at a multidisciplinary tumour board before a plan is set. For the full treatment pathway and what to expect, see Lymphoma Treatment in Hyderabad.
Hodgkin lymphoma is one of the most treatable cancers, and for many people it is curable — though outcomes vary by individual. Treatment usually combines combination chemotherapy with, in some cases, precision radiation therapy (IMRT) to affected node areas; the exact plan depends on the stage and risk features. For Reed-Sternberg cells carrying CD30, antibody-based (anti-CD30) therapy may be used, and immune-checkpoint approaches are options in selected relapsed disease. CION delivers chemotherapy, antibody therapy, immunotherapy and radiation directly; stem-cell transplant, when needed for relapsed disease, is coordinated through accredited partner facilities. We do not name specific drug regimens here — your team will explain the exact protocol. Explore options for relapsed Hodgkin lymphoma or start with a free second opinion.
The outlook for Hodgkin lymphoma is among the best of all cancers. Across published international series, long-term survival for Hodgkin lymphoma is commonly reported at around 80–90%, and higher still for early-stage disease found and treated promptly — considerably better than the roughly 60–70% typically cited for the common non-Hodgkin subtype, diffuse large B-cell lymphoma (per published series and NCCN/ESMO-referenced data). Figures vary by individual, by stage, age and how the disease responds to treatment, so they are a general guide rather than a personal prediction. Because treatment works so well, modern care also focuses on using the least therapy needed to protect long-term health. See detailed, attributed figures on our Hodgkin lymphoma survival & cure rates page.
Browse our complete guide to lymphoma — symptoms, diagnosis, Hodgkin and non-Hodgkin subtypes, treatment, genetics, prognosis, survivorship and cost. Tap any topic to read more.